Neuroleptický maligní syndrom v České republice
| Title in English | Neuroleptic malig-nant syndrome in the Czech Republic |
|---|---|
| Authors | |
| Year of publication | 2023 |
| Type | Article in Periodical |
| Magazine / Source | Česká a slovenská psychiatrie |
| MU Faculty or unit | |
| Citation | |
| Web | http://www.cspsychiatr.cz/dwnld/CSP_2023_3_98_101.pdf |
| Keywords | health care statistics; neuroleptic malignant syndrome; pharmacovigilance |
| Description | Aim: The aim of this paper is to obtain and analyse available data about malignant neuroleptic syndrome (NMS), further, to compare these data with other countries and consider their representative value. Methods: We have used requested data from State Institute for Drug Control, Department of Pharmacovigilance and statis-tical data from the Institute of Health Information and Statistics of the Czech Republic Results: Since the establishment of Pharmacovigilance Department in 2004 till the half of 2020 year there were recorded 13 medically verified NMS cases, 4 of them with fatal outcome. The NMS development has been associated with application of an-tipsychotics of both, the first and second generation. No differences have been found among drug formulations and drug combi-nations were associated with a greater risk of NMS. During the period 2010-2019 ac-cording to data from the Institute of Health Information and Statistics of the Czech Republic 214 patients with admission di-agnosis of NMS were hospitalized in Czech Republic and out of them 11 patients died. The dataset includes mainly demographic data, diagnoses, and medical procedures. Conclusions: By indirect comparison of both sources, we can see discrepancies in the number of cases. Besides aims and methods, other factors may be involved in these inconsistences. An influenceable fac-tor lies in respecting the law on reporting serious side effects. |